The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Opoku Acheampong, Alexander B ^a   Nelsen, Michelle K ^a   Unis, Dave ^a   Lindshield, Brian L ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; MIBOLERONE; TESTOSTERONE; AZASTEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; SEMINAL VESICLE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG SCREENING; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; RAT; TUMOR CELL LINE;

MUS MUSCULUS; RATTUS;

ANIMALS; AZASTEROIDS; BODY WEIGHT; CELL LINE, TUMOR; CELL SURVIVAL; DIHYDROTESTOSTERONE; FINASTERIDE; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RATS; TESTOSTERONE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855368261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029068     Document Type: Article

References (33)

1. American Cancer Society (2011) Cancer facts & figures 2011.
2. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, et al. (2004) Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (3): 537-543.
3. Grossmann ME, (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93 (22): 1687-1697.
4. Russell DW, Wilson JD, (1994) Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem 63: 25-61.
5. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, et al. (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12 (1): 101-107.
6. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB, (2003) Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 57 (2): 134-139.
7. Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, et al. (2005) Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11 (12): 4365-4371.
8. Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad L, et al. (2001) Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 86 (2): 855-858.
9. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, et al. (1997) Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 82 (7): 2210-2214.
10. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, et al. (1999) Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (5-6): 189-195.
11. Habib F, Ross M, Bayne C, Bollina P, Grigor K, et al. (2003) The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clinical Cancer Research 9 (5): 1815-1819.
12. Nickel JC, (2004) Comparison of clinical trials with finasteride and dutasteride. Reviews in Urology 6 (Suppl 9): S31-S39.
13. Geller J, (1991) Overview of enzyme inhibitors and anti-androgens in prostatic cancer. J Androl 12 (6): 364-371.
14. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (3): 215-224.
15. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, et al. (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362 (13): 1192-1202.
16. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Available: . Accessed 2011 Nov 21.
17. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT, (2006) Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (13): 4072-4079.
18. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, et al. (2007) Combinations of tomato and broccoli enhance antitumor activity in dunning R3327-H prostate adenocarcinomas. Cancer Res 67 (2): 836-843.
19. Isaacs JT, Isaacs WB, Feitz WF, Scheres J, (1986) Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9 (3): 261-281.
20. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, et al. (2001) Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 47 (1): 1-13.
21. Bello D, (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18 (6): 1215-1223.
22. Lindshield BL, Ford NA, Canene-Adams K, Diamond AM, Wallig MA, et al. (2010) Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. PLoS One 5 (4): e10423-e10423.
23. Klus GT, Nakamura J, Li JS, Ling YZ, Son C, et al. (1996) Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res 56 (21): 4956-4964.
24. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS, (2004) Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58 (2): 130-144.
25. Long BJ, (2000) Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60 (23): 6630-6640.
26. Sedelaar JPM, Isaacs J, (2009) Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 69 (16): 1724-1729.
27. Geller J, (1979) Steroid levels in cancer of the prostate-markers of tumour differentiation and adequacy of anti-androgen therapy. J Steroid Biochem Mol Biol 11 (1): 631-6.
28. Titus MA, (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 (13): 4653-4657.
29. Das K, Lorena PDN, Ng L, Lim D, Shen L, et al. (2010) Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 17 (3): 757-70.
30. Song Y, Tangen C, Goodman P, Parnes H, Lucia MS, et al. (2008) Finasteride, prostate cancer, and weight gain: Evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Prostate 68 (3): 281-286.
31. Reckelhoff JF, (1999) Gender differences in hypertension in spontaneously hypertensive rats: Role of androgens and androgen receptor. Hypertension 34 (4): 920-923.
32. Shao TC, (1993) Effects of finasteride on the rat ventral prostate. J Androl 14 (2): 79-86.
33. George FW, Russell DW, Wilson JD, (1991) Feed-forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci U S A 88 (18): 8044-8047.